Illumina (ILMN) Optics for Genomics Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Illumina (ILMN) Optics for Genomics

ILMN 119.97

-2.9%

Nov 3 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: A.J. Mullen	11/13/2006 10:58:17 AM
	Read Replies (1) of 276

Illumina Buying Solexa By TSC Staff 11/13/2006 7:10 AM EST Illumina (ILMN - commentary - Cramer's Take) agreed to buy Solexa (SLXA - commentary - Cramer's Take) for $14 a share, or $600 million in stock, in a merger of genetic science players. The deal gives holders of Hayward, Calif.-based Solexa a 45% premium to Friday's closing price. San Diego-based Illumina will also buy $50 million worth of new Solexa shares. The companies said Illumina and Solexa will create the only company with genome-scale technology for genotyping, gene expression and sequencing, the three cornerstones of modern genetic analysis. This exchange ratio will be determined by dividing $14 by the volume weighted average trading price of Illumina common stock as reported by Nasdaq during 10 randomly selected days during the 20-day trading period ending five trading days prior to closing. However, if the Illumina average price is equal to or greater than $47.30, then the exchange ratio will be fixed at 0.296, and if the Illumina average price is equal to or less than $40.70, then the exchange ratio will be fixed at 0.344.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next